The development and evaluation of a new burden of disease instrument for COPD.

The development and evaluation of a new burden of disease instrument for COPD. The COPD Impact Scale.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON26129

Enrollment

360

Registered

2013-01-11

Start date

2013-02-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

Participants in the intervention group will receive treatment, based on the newly developed COPD Impact Scale (CIS) and a treatment-algorithm. Patients will fill out the CIS, and additionally the care

Eligibility

Inclusion criteria

Inclusion criteria: 1. Spirometrically confirmed diagnosis of COPD (post-bronchodilatatoir FEV1/FVC < 0.7); 2. Age 40+; 3. Patient is competent enough to understand and read the Dutch language.

Exclusion criteria

Exclusion criteria: 1. Exacerbations < 6 weeks; 2. Hard drug addiction; 3. Life-threatening co-morbid condition; 4. Pregnancy.

Design outcomes

Primary

Measure	Time frame
The difference in health-related quality of life between baseline and 18-months follow-up, measured by the St George’s Respiratory Questionnaire.	—

Secondary

Measure	Time frame
1. The difference in health-related quality of life between baseline and 6-months and 12-months follow-up, measured by the St George’s Respiratory Questionnaire; 2. The difference in health-related quality of life between baseline and 18-months follow-up, measured by the COPD Assessment Test; 3. Differences will be calculated between baseline and 18-months follow up on the EuroQol 5d; 4. Number of exacerbations at 12 months and 18 months.	—

Measure

Time frame

1. The difference in health-related quality of life between baseline and 6-months and 12-months follow-up, measured by the St George’s Respiratory Questionnaire; 2. The difference in health-related quality of life between baseline and 18-months follow-up, measured by the COPD Assessment Test; 3. Differences will be calculated between baseline and 18-months follow up on the EuroQol 5d; 4. Number of exacerbations at 12 months and 18 months.

—

Contacts

Public ContactAnnerika Slok

PO Box 616

annerika.slok@maastrichtuniversity.nl+31 (0)43 3882997

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)